Journal
HUMAN VACCINES & IMMUNOTHERAPEUTICS
Volume 16, Issue 1, Pages 109-111Publisher
TAYLOR & FRANCIS INC
DOI: 10.1080/21645515.2019.1636598
Keywords
Acute myeloid leukemia; histamine dihydrochloride; IL-2; immunotherapy; relapse prevention; normal karyotype
Categories
Funding
- Cancerfonden [CAN 2016/351]
- Vetenskapsradet [2016-01928]
- Swedish Research Council [2016-01928] Funding Source: Swedish Research Council
- Vinnova [2016-01928] Funding Source: Vinnova
Ask authors/readers for more resources
Immunotherapy with histamine dihydrochloride and low-dose interleukin-2 (HDC/IL-2) reduces the risk of relapse in the post-chemotherapy phase of acute myeloid leukemia (AML). Here we report the results of exploratory analyses of the clinical efficacy of HDC/IL-2 in AML with focus on the impact of karyotype aberrations in leukemic cells. Post-hoc analyses of phase III trial data suggested that HDC/IL-2 is primarily beneficial for patients with AML of normal karyotype. These results may be helpful in the selection of patients who are suitable for therapy and in the design of future immunotherapy protocols aiming at further defining the mechanism of relapse prevention by HDC/IL-2.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available